share_log

Biodexa Pharmaceuticals | 424B3: Prospectus

SEC announcement ·  May 29 21:08
Summary by Futu AI
Biodexa Pharmaceuticals PLC, a company listed on NASDAQ under the symbol BDRX, has filed a prospectus supplement with the Securities and Exchange Commission (SEC) on May 29, 2024. This filing amends and supplements the prospectus dated December 18, 2023, related to the offering of Class A and Class B Units. The Class A Units consist of American Depositary Shares (ADSs), Series E Warrants, and Series F Warrants, while the Class B Units include Pre-Funded Warrants, Series E Warrants, and Series F Warrants, along with Representative Warrants. The company has also filed a Form 6-K, reporting the closing of a transaction with accredited investors who exercised their existing Series E and Series F Warrants, resulting in the issuance of replacement Series G and Series H Warrants. The transaction generated approximately $6.05 million in gross proceeds for Biodexa Pharmaceuticals before expenses. Additionally, placement agent warrants were issued to Ladenburg Thalmann & Co., Inc. The company's ADSs, representing ordinary shares, closed at $1.08 on the NASDAQ Capital Market on May 28, 2024.
Biodexa Pharmaceuticals PLC, a company listed on NASDAQ under the symbol BDRX, has filed a prospectus supplement with the Securities and Exchange Commission (SEC) on May 29, 2024. This filing amends and supplements the prospectus dated December 18, 2023, related to the offering of Class A and Class B Units. The Class A Units consist of American Depositary Shares (ADSs), Series E Warrants, and Series F Warrants, while the Class B Units include Pre-Funded Warrants, Series E Warrants, and Series F Warrants, along with Representative Warrants. The company has also filed a Form 6-K, reporting the closing of a transaction with accredited investors who exercised their existing Series E and Series F Warrants, resulting in the issuance of replacement Series G and Series H Warrants. The transaction generated approximately $6.05 million in gross proceeds for Biodexa Pharmaceuticals before expenses. Additionally, placement agent warrants were issued to Ladenburg Thalmann & Co., Inc. The company's ADSs, representing ordinary shares, closed at $1.08 on the NASDAQ Capital Market on May 28, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.